Literature DB >> 10727446

Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.

G P Rizzardi1, R J De Boer, S Hoover, G Tambussi, A Chapuis, N Halkic, P A Bart, V Miller, S Staszewski, D W Notermans, L Perrin, C H Fox, J M Lange, A Lazzarin, G Pantaleo.   

Abstract

Effective therapeutic interventions and clinical care of adults infected with HIV-1 require an understanding of factors that influence time of response to antiretroviral therapy. We have studied a cohort of 118 HIV-1-infected subjects naive to antiretroviral therapy and have correlated the time of response to treatment with a series of virological and immunological measures, including levels of viral load in blood and lymph node, percent of CD4 T cells in lymph nodes, and CD4 T-cell count in blood at study entry. Suppression of viremia below the limit of detection, 50 HIV-1 RNA copies/mL of plasma, served as a benchmark for a successful virological response. We employed these correlations to predict the length of treatment required to attain a virological response in each patient. Baseline plasma viremia emerged as the factor most tightly correlated with the duration of treatment required, allowing us to estimate the required time as a function of this one measure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10727446      PMCID: PMC377467          DOI: 10.1172/JCI9079

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Examining cells for infectious agents: a novel approach.

Authors:  M Cottler-Fox; C H Fox
Journal:  J Infect Dis       Date:  1991-12       Impact factor: 5.226

2.  Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes.

Authors:  D Emilie; M Peuchmaur; M C Maillot; M C Crevon; N Brousse; J F Delfraissy; J Dormont; P Galanaud
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

3.  Altered follicular dendritic cells and virus-like particles in AIDS and AIDS-related lymphadenopathy.

Authors:  K Tenner-Rácz; P Rácz; M Dietrich; P Kern
Journal:  Lancet       Date:  1985-01-12       Impact factor: 79.321

4.  HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.

Authors: 
Journal:  AIDS       Date:  1999-01-14       Impact factor: 4.177

5.  Lymphoid organs function as major reservoirs for human immunodeficiency virus.

Authors:  G Pantaleo; C Graziosi; L Butini; P A Pizzo; S M Schnittman; D P Kotler; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

6.  HIV in infected lymph nodes.

Authors:  C H Fox; S Hoover; V R Currall; H J Bahre; M Cottler-Fox
Journal:  Nature       Date:  1994-07-28       Impact factor: 49.962

7.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS.

Authors:  J Embretson; M Zupancic; J L Ribas; A Burke; P Racz; K Tenner-Racz; A T Haase
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

8.  Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA.

Authors:  C H Fox; K Tenner-Rácz; P Rácz; A Firpo; P A Pizzo; A S Fauci
Journal:  J Infect Dis       Date:  1991-12       Impact factor: 5.226

9.  Follicular dendritic cells are a major reservoir for human immunodeficiency virus type 1 in lymphoid tissues facilitating infection of CD4+ T-helper cells.

Authors:  H Spiegel; H Herbst; G Niedobitek; H D Foss; H Stein
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

10.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.

Authors:  G Pantaleo; C Graziosi; J F Demarest; L Butini; M Montroni; C H Fox; J M Orenstein; D P Kotler; A S Fauci
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

View more
  6 in total

1.  Benchmarks for antiretroviral therapy.

Authors:  O J Cohen; A S Fauci
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

2.  Clinical, immunological and virological evolution in patients with CD4 T-cell count above 500/mm3: is there a benefit to treat with highly active antiretroviral therapy (HAART)?

Authors:  Lionel Piroth; Christine Binquet; Marielle Buisson; Evelyne Kohli; Michel Duong; Michèle Grappin; Michal Abrahamowicz; Catherine Quantin; Henri Portier; Pascal Chavanet
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

3.  Human herpesvirus 6A accelerates AIDS progression in macaques.

Authors:  Paolo Lusso; Richard W Crowley; Mauro S Malnati; Clelia Di Serio; Maurilio Ponzoni; Angelique Biancotto; Phillip D Markham; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-14       Impact factor: 11.205

4.  Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels.

Authors:  Erik Sörstedt; Staffan Nilsson; Anders Blaxhult; Magnus Gisslén; Leo Flamholc; Anders Sönnerborg; Aylin Yilmaz
Journal:  BMC Infect Dis       Date:  2016-06-21       Impact factor: 3.090

5.  Modelling the evolution of HIV-1 virulence in response to imperfect therapy and prophylaxis.

Authors:  David R M Smith; Nicole Mideo
Journal:  Evol Appl       Date:  2017-02-11       Impact factor: 5.183

6.  Estimating PMTCT's Impact on Heterosexual HIV Transmission: A Mathematical Modeling Analysis.

Authors:  Aditya S Khanna; Sarah T Roberts; Susan Cassels; Roger Ying; Grace John-Stewart; Steven M Goodreau; Jared M Baeten; Pamela M Murnane; Connie Celum; Ruanne V Barnabas
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.